Ramucirumab (RAM), an anti‐VEGF receptor 2 (VEGFR‐2) fully human monoclonal IgG1 antibody, is a member of the antibody class of molecularly targeted therapies that works to inhibit tumor growth by preventing VEGF from binding to VEGFR‐2 and sending angiogenic signals downstream.15 This evidence concerns the gene KDR and neoplasm.